In the podcast series, Thermo Fisher Scientific’s Sr. Product Manager, Linas Pupelis, will discuss latest development of critical raw materials required to support the synthesis of mRNA for therapeutic development. Today, mRNA therapies are one of the hottest drug classes and the development of an entirely new drug class is not without challenges. A major issue in this industry is lack of high-quality raw material that meet clinical research and manufacturing regulations. In this podcast, we will discuss how our TheraPure reagents, which is specifically designed and carefully manufactured following the principles of 21 CFR 210/211 and ICH Q7, can help build the solutions to today’s challenges.